DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Hormone refractory prostate cancer
Cabazitaxel
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following or during docetaxel-based treatment.
Hormone refractory prostate cancer - List of case studies
- Prostatic Adenocarcinoma
-
prostate cancer. At present he has metastatic hormone refractory prostate cancer. His current treatment consists of Estracyt and LHRH ...
- Hepatic metastases from prostatic adenocarcinoma
-
chance that the disease will go a transformation to a hormone refractory prostate cancer . At that stage Taxotere based chemotherapy ...
- Prostatic adenocarcinoma – additional information
-
78-years-old male with poorly differentiated hormone resistant prostate cancer. The expert recommends treatment with ... ) although the disease is already defined as hormone refractory due to the fact that the tumor is heterogenous and some of the ...